ClinicalTrials.gg

Program

surovatamig

Also written as “Surovatamig”, “AZD0486” and “AZD0486 IV”.

Its studies are mostly in Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell · Arthritis, Rheumatoid · Lymphoma, Follicular · Glomerulonephritis, Membranous, led by AstraZeneca.

Furthest: phase 3, since Jul 29, 202410 company-led studies, 10 open or runningNext primary completion: Jan 6, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca1010 open or runningphase 3since Jul 29, 2024Oct 13, 2020Jan 6, 2028phase 2 · NCT06137118
  • Named in AstraZeneca’s own pipeline as surovatamig, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 13, 2020First study: phase 1 study in Lymphoma, B-CellFirst studyNCT04594642 · 226 enrolled · United States, Australia, Japan and more
  2. Nov 3, 2023Phase 2 study in Burkitt LymphomaNCT06137118 · 255 planned · United States, Australia, Brazil and more
  3. Jul 3, 2024Phase 2 study in Lymphoma, B-CellNCT06526793 · 270 planned · United States, Australia, Brazil and more
  4. Jul 29, 2024Phase 3 study in Lymphoma, FollicularNCT06549595 · 1,018 planned · United States, Australia, Belgium and more
  5. Aug 19, 2024Phase 2 study in Leukemia, B-CellNCT06564038 · 408 planned · United States, Australia, China and more
  6. Sep 30, 2025Phase 1 study in Arthritis, RheumatoidNCT07201558 · 48 planned · United States, Australia, Belgium and more
  7. Oct 7, 2025Phase 3 study in Large B-cell LymphomaNCT07215585 · 420 planned · Australia, Belgium, Brazil and more
  8. Mar 19, 2026Phase 2 study in Primary Membranous NephropathyNCT07571746 · 43 planned · United States, Belgium, China and more
  9. Mar 27, 2026Phase 3 study in Leukemia, B-CellNCT07509151 · 420 planned · United States, Australia, Canada and more
  10. Oct 20, 2026Primary completion moved from 2028-04-24 to 2028-10-13Date moved laterphase 2 · +6 months · NCT07571746
  11. Oct 26, 2026Phase 3 study in Lymphoma, B-CellNCT07911553 · 1,200 planned
  12. Oct 28, 2026Primary completion moved from 2029-06-11 to 2030-05-20Date moved laterphase 2 · +11 months · NCT06564038

Ahead

  1. Jan 6, 2028Primary completion: phase 2 study in Burkitt LymphomaNCT06137118
  2. Apr 21, 2028Primary completion: phase 2 study in Lymphoma, B-CellNCT06526793
  3. Jun 19, 2028Primary completion: phase 1 study in Lymphoma, B-CellNCT04594642
  4. Jun 27, 2028Primary completion: phase 1 study in Arthritis, RheumatoidNCT07201558

TargetBeta

“A human bispecific T-cell engager antibody composed of a fixed-light-chain (FLC) arm targeting the CD3 antigen found on T-lymphocytes and a heavy-chain-only (HCO) arm targeting the B-cell-specific membrane protein CD19, with potential immunostimulating and antineoplastic activities. Upon administ…”NCIt, read by Claude
“A human bispecific T-cell engager antibody composed of a fixed-light-chain (FLC) arm targeting the CD3 antigen found on T-lymphocytes and a heavy-chain-only (HCO) arm targeting the B-cell-specific membrane protein CD19, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
YK012ruleexcyte-biopharma-ltdphase 25
GSK5926371GlaxoSmithKlinephase 22
Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rulecullinan-therapeutics-incphase 14
Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rulecytocares-incphase 14
Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565Novartisphase 13
ATG-201ruleantengene-biologics-limitedphase 11
KT501rulekali-therapeutics-incphase 11
KT502rulekali-therapeutics-incphase 11

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07911553Lymphoma, B-Cell3Not yet recruitingSep 2, 20301,200
NCT07509151Leukemia, B-Cell · United States, Australia, Canada and more3RecruitingAug 29, 2031420
NCT07571746Primary Membranous Nephropathy · United States, Belgium, China and more2RecruitingOct 13, 202843
NCT07215585Large B-cell Lymphoma · Australia, Belgium, Brazil and more3RecruitingJun 10, 2030420
NCT07201558Arthritis, Rheumatoid · United States, Australia, Belgium and more1RecruitingJun 27, 202848
NCT06564038Leukemia, B-Cell · United States, Australia, China and more2RecruitingMay 20, 2030408
NCT06549595Lymphoma, Follicular · United States, Australia, Belgium and more3RecruitingNov 26, 20311,018
NCT06526793Lymphoma, B-Cell · United States, Australia, Brazil and more2RecruitingApr 21, 2028270
NCT06137118Burkitt Lymphoma · United States, Australia, Brazil and more2RecruitingJan 6, 2028255
NCT04594642Lymphoma, B-Cell · United States, Australia, Japan and more1Active, not recruitingJun 19, 2028226

How it is read

Names in the registry

  • “Surovatamig”, 8 entries
  • “AZD0486”, 1 entry
  • “AZD0486 IV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.